The firm's total revenue increased 48 percent as oncology revenue grew 36 percent and biopharma and data revenue rose 17 percent.
The firm said that volume-based procurement headwinds facing its diagnostics business in China created a perfect storm with previously announced restructuring plans.
NEW YORK – Multimodal artificial intelligence-based prognostic and predictive oncology test developer Artera announced on Wednesday that the US Food and Drug Administration has cleared its risk ...
NEW YORK – Digital pathology firm Waiv announced on Wednesday that it has entered into a collaboration with pharmaceutical company Daiichi Sankyo to lead digital pathology biomarker discovery for an ...
Tempus will build a care gap program to help identify patients who may benefit from Quanterix's Alzheimer's test and will make it available through its clinical ordering platform.
The test is designed to detect a marker of hepatitis B infection at the point of care, with results in 15 minutes.
The senator requested answers to questions about the precise reason for the suspension and how many staff positions at the agency have been eliminated.
Last week, readers were most interested in an update from ESCMID on companies' plans for their rapid molecular diagnostic platforms and tests.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results